REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

Event · M&A · completed
Role
acquirer
Counterparty
BioLife Solutions, Inc.
Consideration
mixed
Price per share
$11.25 per share

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 6, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$RGEN
Bullish
high confidence
Mentioned
$RGEN · $BLFS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RGENBullishHigh
01

Why it matters

The deal expands Repligen's product portfolio and recurring revenue, likely supporting a share price rally, while BioLife will be absorbed.

02

Market read

First‑report of a material M&A transaction in the biotech sector; immediate price impact expected for RGEN.

03

What to watch

Regulatory approvals for combined product lines and potential antitrust scrutiny could delay synergies.

Relevance 8/10Novelty 8/10Timing: today (Oct 6, 2026)

Background

Repligen (NASDAQ:RGEN) completed its previously announced acquisition of BioLife Solutions (NASDAQ:BLFS), a supplier of cell‑processing tools for gene‑therapy markets.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

Repligen announced completion of its acquisition of BioLife Solutions, receiving cash and stock, a material M&A event.

Expected impact

likely upward pressure as investors price in synergies and revenue expansion

Evidence & confidence

The deal adds high‑margin consumables and broadens market reach; cash component and stock issuance are modest, suggesting accretive effect.

$BLFSNeutralHigh confidence
Context

BioLife shareholders received cash and Repligen stock for their shares as part of the completed acquisition.

Expected impact

stock will be delisted; former shareholders benefit from cash and Repligen shares

Evidence & confidence

The transaction ends BLFS as a standalone entity; price impact is limited to the transaction terms.

Market effects

Strengthens the bioprocessing and cell‑therapy supply chain, potentially boosting related equipment and consumable providers.

Adds to U.S. biotech M&A activity; modest impact on European peers.

Highlights growing demand for cell‑therapy manufacturing, may influence global biotech funding trends.

Counterpoint

If integration costs exceed expectations, the acquisition could dilute RGEN earnings and pressure the stock.

Key entities

  • Repligen Corporation

    Life‑sciences firm acquiring BioLife.

  • BioLife Solutions, Inc.

    Cell‑processing tools provider being acquired.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.